Financial Statements, Auditor Correction, and Company Overview – Minichart

Immix Biopharma, Inc. Files Amfinishment No. 1 to Annual Report on Form 10-K/A: Key Highlights for Investors

Summary of the Amfinishment

Immix Biopharma, Inc. (Nasdaq: IMMX), a Los Angeles-based biopharmaceutical company, has filed Amfinishment No. 1 to its Annual Report on Form 10-K/A for the fiscal year finished December 31, 2025. This amfinishment was submitted to reflect the correct date of the Report of Indepfinishent Registered Public Accounting Firm (Auditor Report), which is now properly stated as March 25, 2026. According to the filing, no other modifys have been created to the financial reports or the 10-K content compared to the version filed on March 25, 2026.

The amfinishment also includes currently-dated auditor consent and certifications from the Company’s Chief Executive Officer and Chief Financial Officer. These documents are filed as exhibits to this amfinishment, complying with SEC requirements. No other information from the original filing has been amfinished or updated.

Key Financial Highlights

Comprehensive Loss: The Company reported a comprehensive loss of \$29.4 million for the year finished December 31, 2025, compared to a comprehensive loss of \$21.7 million in 2024. This increase in loss may be a point of concern for shareholders, indicating growing expenses or reduced revenues.
Net Loss: The net loss for 2025 was \$29.3 million, up from \$21.6 million in 2024.
Loss Per Share: Basic and diluted loss per common share was (\$0.89) in 2025 compared to (\$0.76) in 2024. This reflects a deterioration in per-share results year-over-year.
Weighted Average Shares Outstanding: The weighted average number of shares outstanding (basic and diluted) increased to 32,965,706 in 2025 from 28,285,637 in 2024, reflecting share issuances during the year.
Common Stock: As of December 31, 2025, there were 52,951,103 shares of common stock outstanding, up from 27,540,020 shares at the finish of 2024. As of March 20, 2026, the number was 52,964,549 shares.
Cash and Cash Equivalents: The company’s cash and cash equivalents stood at \$22.95 million at December 31, 2025.
Total Stockholders’ Equity: Stockholders’ equity was reported at \$13.25 million at year-finish 2024 and increased to \$16.2 million at year-finish 2025.

Capital and Financing Activities

Other Corporate Actions

Non-controlling Interests: The Company completed a acquireout of non-controlling interests in a subsidiary, involving the issuance of 989,876 shares. This transaction may have implications for the Company’s control and future earnings allocation.
Shares Issued for Services: Immix Biopharma issued 239,210 shares for services rfinishered, valued at \$627,376. This non-cash compensation could be indicative of the company’s efforts to conserve cash while attracting or retaining talent or consultants.
Internal Controls: The Company is not required to have, nor has it engaged, an audit of its internal control over financial reporting. There is no auditor attestation under Section 404(b) of the Sarbanes-Oxley Act, which may be important for certain institutional investors.

Shareholder and Regulatory Information

Filing Status: Immix Biopharma is classified as a non-accelerated filer and a tinyer reporting company, which may impact the frequency and depth of SEC reporting requirements.
Exmodify Listing: The Company’s common stock trades on the Nasdaq Stock Market LLC under the symbol IMMX.
No Restatement or Error Correction: The financial statements included in this amfinishment do not reflect corrections of previously issued statements and there are no restatements or recovery analysis required for executive incentive-based compensation.
Proxy Statement: Portions of the Company’s 2026 Proxy Statement, to be filed within 120 days after year-finish, will be incorporated by reference into Part III of this Annual Report.

Potential Price-Sensitive Items for Shareholders

Significant Dilution: The substantial increase in shares outstanding due to equity offerings and private placements may be dilutive to existing shareholders but has significantly increased the Company’s cash reserves and operational runway.
Increased Operating Loss: The marked increase in net and comprehensive loss year-over-year could impact investor sentiment and share price, especially if it signals accelerating R&D spfinish or slower-than-expected progress toward commercialization.
Capital Position: The robust cash position at year-finish 2025 (\$22.95 million) and increased equity capital suggest the Company is well-funded for its near-term development goals, which could be viewed positively, especially in the biotech sector where capital necessarys are high.
No Material Changes Except Auditor Report Date: The only modify in this amfinishment is the corrected date of the auditor report. Investors should be aware that no new material events or modifys to the business or financials are disclosed in this amfinishment.

Conclusion

In summary, this amfinishment is administrative in nature, correcting only the date of the auditor’s report, with no modifys to previously reported financials or operations. The underlying financial results, however, display significant capital-raising activity, a large increase in shares outstanding, and growing operating losses. Shareholders should pay close attention to the dilution from new issuances and the Company’s continued net losses, though the strengthened balance sheet may support ongoing R&D and business development efforts.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before creating investment decisions. The information provided is based on the Company’s SEC filings and may be subject to modify or updates.